Portal Hypertension, Liver Cirrhosis
Conditions
Interventions
MPH Patient Group (Part One):None
Healthy Control Group (Part One:None
CSPH patient Group (Part Two):None
MPH Patient Group (Part Two):None
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Part 1: Early Prediction of Mild Portal Hypertension (MPH) 1. Case Group - MPH Patients (1) Age >= 18 years; (2) Pathologically diagnosed with cirrhosis and confirmed as MPH by HVPG measurement (5 mm Hg = 18 years; (2) No history of cirrhosis and HVPG = 18 years; (2) Pathologically diagnosed with cirrhosis and confirmed as CSPH by HVPG measurement (HVPG >= 10 mmHg); (3) Planned to undergo contrast-enhanced upper abdominal MRI and 4D-flow MRI. 2. Control Group - MPH Patients (1) Age >= 18 years; (2) Pathologically diagnosed with cirrhosis and confirmed as MPH by HVPG measurement (5 mm Hg <= HVPG <= 10 mmHg); (3) Planned to undergo contrast-enhanced upper abdominal MRI and 4D-flow MRI.
Exclusion criteria
Exclusion criteria: Part 1: Early Prediction of Mild Portal Hypertension (MPH) Case Group - MPH Patients 1. Coexisting pathologically confirmed liver-related neoplastic lesions, such as hepatocellular carcinoma or cholangiocarcinoma; 2. Contraindications to MRI preventing upper abdominal contrast-enhanced MRI; 3. Poor MR image quality rendering data analysis impossible; 4. Pathologically confirmed other malignancies; 5. Other conditions deemed ineligible by the investigator. Part 2: Risk Stratification and Prognostic Assessment of Clinically Significant Portal Hypertension (CSPH) Case Group - CSPH Patients 1. Coexisting pathologically confirmed liver-related neoplastic lesions, such as hepatocellular carcinoma or cholangiocarcinoma; 2. Contraindications to MRI preventing upper abdominal contrast-enhanced MRI; 3. Poor MR image quality rendering data analysis impossible; 4. Pathologically confirmed other malignancies; 5. Other conditions deemed ineligible by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemodynamic parameters of the portal venous system (including turbulent kinetic energy, TKE, and pressure difference, PD); | — |
Secondary
| Measure | Time frame |
|---|---|
| HVPG level grouping (>=12 mmHg, >=16 mmHg, >=20 mmHg);Clinical endpoint events (refractory ascites, bleeding, recurrent bleeding, failed bleeding control, death, progression-free survival [PFS], and overall survival [OS]);Area under the ROC curve (AUC), sensitivity, specificity, and accuracy;Intraclass correlation coefficient (ICC); | — |
Countries
China
Contacts
Public ContactWan Shang
West China Hospital, Sichuan University
Outcome results
None listed